News

Amgen Inc. - STAT Coverage of the Giant Multinational Biotech Firm

Market 72/100How we got 72/100Source tierEstablished referenceTier ceiling72/100Independent sourcesnot recordedPublished score72/100Scored at the ceiling for a established reference source — it cannot go higher. The number is the source page’s own score, hard-capped at the tier ceiling; corroboration is recorded but cannot lift a score past that cap. Under 40 a claim goes to review instead of publication. Full methodology →
July 28, 2026↗ source

This article serves as a STAT news hub covering Amgen Inc., featuring a collection of headlines regarding the company's business and clinical pipeline. It specifically highlights Amgen's position in the competitive GLP-1 weight loss drug market, referencing their candidate MariTide (AMG 133). The coverage notes clinical trial outcomes, including high discontinuation rates in mid-stage studies and subsequent dosing adjustments.

Related peptides

GLP-1NOTAVersaN-peptidePeptide T
We summarize, we don't invent — every detail here traces to a real, linked source, and the badge reflects how trustworthy that source is. Read the original and decide for yourself.